Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 7/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | HEXA | P06865 | 3/20 | 0.31 |
| ▸ | HEXB | P07686 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628166 | 0.76 | HEXA (0.50) | DHFRHEXAHEXBALDH1A1CYP2D6 | |
| SCHEMBL13653845 | 0.70 | HEXA (0.41) | DHFRHEXAHEXBALDH1A1CYP2D6 | |
| SCHEMBL28151078 | 0.69 | DHFR (0.57) | DHFRHEXAHEXBALDH1A1CYP2D6 | |
| SCHEMBL16966518 | 0.65 | HEXA (0.59) | DHFRHEXAHEXBCYP2D6REN | |
| SCHEMBL12484463 | 0.63 | HEXA (0.48) | DHFRHEXAHEXBALDH1A1CYP2D6 | |
| SCHEMBL12131262 | 0.62 | — | — | |
| SCHEMBL22080186 | 0.60 | TP53 (0.44) | ALDH1A1 | |
| SCHEMBL1359353 | 0.60 | PIK3CA (0.47) | DHFR | |
| SCHEMBL6345470 | 0.57 | KMT2A (0.47) | DHFRHEXAHEXBALDH1A1CYP2D6 | |
| SCHEMBL15748053 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820648-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | CCNB1, TYMS, CCNA1 | DHFR 181/4885PDPK1 712/4885GDA 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.